



News Release

FOR IMMEDIATE RELEASE

Contact: Ronald Trahan, APR, Ronald Trahan Associates Inc., 508-359-4005, x108

**Study demonstrates that Muscular CounterPulsation —
the basis of Cardiola's m.pulse® system —
is “safe and efficient for improving cardiac function”
non-surgically in patients with coronary artery disease (CAD)**

**Data presented at the Annual Congress of
the Swiss Society of Cardiology**

**“Muscular counterpulsation is completely non-invasive and
simple to use with a portable pulse-generating device.”**

Prof. Beat Walpoth, Director, Cardiovascular Research
Clinical and Experimental, University Hospital, Geneva

WINTERTHUR, Switzerland, June 23, 2009—[Cardiola AG](#) announced today that data from a study (“Safety and efficacy of ECG-triggered muscular counterpulsation for hemodynamic improvement of cardiac function”) presented at the recently convened Annual Congress of the Swiss Society of Cardiology demonstrates that “MCP (muscular counterpulsation) is safe and efficient for improving cardiac function in patients with coronary artery disease (CAD). One of the study’s investigators was **Prof. Beat Walpoth**, Director of Cardiovascular Research, Clinical and Experimental, at University Hospital in Geneva, Switzerland.

In the study, **peripheral resistance** of CAD patients was decreased by 22%; **end-diastolic pressure** was reduced by 18%; and **stroke work** was reduced by 16%. Additionally, there was a 12% increase in **cardiac index**. Equally important, all of these hemodynamic effects were less marked in the study’s control patients.

“Given the promising results of this and many previous clinical studies, it is well-established that MCP—the proprietary technology platform of our patented *m.pulse®* device—is a safe and effective therapy designed to improve the hemodynamic function of a failing heart,” said **Christof Lenz**, **Cardiola’s CEO and former Global Innovation Manager at Siemens Medical**. “With regulatory approval now in place in Europe, the *m.pulse®* system is offering patients a *well-validated, affordable and non-surgical* treatment alternative that they themselves can perform *in their own home*.”

Cardiola’s *m.pulse®* device, based on **Muscular CounterPulsation (MCP)** technology, is approved in Europe for treating CHF as a nonsurgical, at-home therapy. Battery-powered *m.pulse®*, the size of a cell phone that the patient attaches to his belt for about 45 minutes per treatment, is synchronized to his cardiac cycle to stimulate the muscles of the calves and thighs to make them contract *in the resting phase of the heart*. This well-established *counterpulsation* action results in increased blood flow to the heart muscle while decreasing the heart’s workload. Counterpulsation was previously only available in a clinical setting. Now, *m.pulse®* is **the world’s first and only device enabling CHF patients to receive MCP therapy at home**.

Chronic Heart Failure is among the world's most prevalent diseases and the cause of numerous other serious clinical disorders. Approximately 17 million people currently suffer from CHF in Europe, the U.S. and Japan. Some six million of these patients are classified as NYHA (New York Heart Assn.) classes II and III with systolic dysfunction, the primary patient population for *m.pulse*® with **Muscular CounterPulsation** from Cardiola.

#####